Testosterone supplementary therapy for type-2 diabetes mellitus males with hypogonadism: Controversy and analysis.
- Author:
Zhen CHENG
1
;
Lu-Yao ZHANG
1
;
Guan-Ming CHEN
1
;
Wei HE
2
;
Ke CAI
1
;
Zhi-Hong LIAO
1
Author Information
1. Department of Endocrine and Metabolic Diseases, The First Hospital Affiliated to Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
2. Department of Ultrasound, The First Hospital Affiliated to Sun Yat-sen University, Guangzhou, Guangdong 510080, China..
- Publication Type:Journal Article
- Keywords:
hypogonadism;
testosterone supplementary therapy;
type-2 diabetes mellitus
- MeSH:
Androgens;
deficiency;
Blood Glucose;
Cardiovascular Diseases;
etiology;
Diabetes Mellitus, Type 2;
etiology;
Hormone Replacement Therapy;
Humans;
Hypogonadism;
complications;
diagnosis;
drug therapy;
Male;
Meta-Analysis as Topic;
Randomized Controlled Trials as Topic;
Testosterone;
physiology;
therapeutic use
- From:
National Journal of Andrology
2017;23(8):739-744
- CountryChina
- Language:Chinese
-
Abstract:
As more and more studies suggest that type 2 diabetes mellitus (T2DM) is closely related to male hypogonadism, people begin to pay more attention to the role of testosterone in the development of T2DM and the effect and safety of testosterone supplementary therapy. There is some controversy in randomized controlled studies and meta-analyses about the effects of testosterone supplementation on the blood glucose level, androgen deficiency symptoms, and cardiovascular diseases. This review focuses on the diagnosis of hypogonadism in T2DM males, differences in the therapeutic effects and safety of testosterone replacement among different studies, and rational use of testosterone supplementation for T2DM patients.
